Table 3.
Uterine adenosarcoma systematic review patient demographics (n = 230).
| Characteristic | No. (%) |
|---|---|
| Age (y) | 57.3 (±16.1) |
| ≥60 | 109 (47.4%) |
| <60 | 108 (47.0%) |
| Unknown | 13 (5.6%) |
| Area of publication | |
| North America | 188 (81.8%) |
| Asia | 28 (12.2%) |
| Europe | 10 (4.3%) |
| Others | 4 (1.7%) |
| Year of publication | |
| 1974–1999 | 106 (46.1%) |
| 2000–2009 | 20 (8.7%) |
| 2010–2015 | 104 (45.2%) |
| Stage | |
| I | 179 (77.8%) |
| II | 21 (9.1%) |
| III | 15 (6.5%) |
| IV | 8 (3.5%) |
| Unknown | 7 (3.1%) |
| Myometrial invasion | |
| ≤50% | 139 (60.4%) |
| >50% | 21 (9.2%) |
| Unknown | 70 (30.4%) |
| Sarcomatous overgrowth | |
| No | 68 (29.6%) |
| Yes | 91 (39.6%) |
| Unknown | 71 (30.9%) |
| Heterologous components | |
| No | 119 (51.7%) |
| Yes | 35 (15.2%) |
| Unknown | 76 (33.3%) |
| Lymph node metastasis | |
| No | 122 (53.0%) |
| Yes | 9 (4.0%) |
| Unknown | 99 (43.0%) |
| Surgery type | |
| Total/pan/simple hyst | 217 (94.3%) |
| Other hysterectomy | 13 (5.7%) |
| Adjuvant radiation | |
| No | 188 (81.7%) |
| Yes | 35 (15.3%) |
| Unknown | 7 (3.0%) |
| Adjuvant chemotherapy | |
| No | 197 (85.7%) |
| Yes | 26 (11.3%) |
| Unknown | 7 (3.0%) |
Number (%) or mean (±SD) is shown. Abbreviations: hyst, hysterectomy.